DK1600460T3 - Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL - Google Patents

Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL

Info

Publication number
DK1600460T3
DK1600460T3 DK04078136T DK04078136T DK1600460T3 DK 1600460 T3 DK1600460 T3 DK 1600460T3 DK 04078136 T DK04078136 T DK 04078136T DK 04078136 T DK04078136 T DK 04078136T DK 1600460 T3 DK1600460 T3 DK 1600460T3
Authority
DK
Denmark
Prior art keywords
cll
preparation
treatment
pharmaceutical composition
active compound
Prior art date
Application number
DK04078136T
Other languages
English (en)
Inventor
Thomas Hanke
Original Assignee
Theramab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramab Llc filed Critical Theramab Llc
Application granted granted Critical
Publication of DK1600460T3 publication Critical patent/DK1600460T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04078136T 2003-11-11 2004-11-11 Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL DK1600460T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2003152900 DE10352900A1 (de) 2003-11-11 2003-11-11 Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL

Publications (1)

Publication Number Publication Date
DK1600460T3 true DK1600460T3 (da) 2012-11-19

Family

ID=34585025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04078136T DK1600460T3 (da) 2003-11-11 2004-11-11 Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL

Country Status (6)

Country Link
US (4) US20060008457A1 (da)
EP (1) EP1600460B1 (da)
DE (1) DE10352900A1 (da)
DK (1) DK1600460T3 (da)
ES (1) ES2391455T3 (da)
PT (1) PT1600460E (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
ES2437571T3 (es) * 2004-11-11 2014-01-13 Theramab Llc Anticuerpos anti-CD28 superagonistas
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
SG190627A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
RU2540013C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
JP5597553B2 (ja) * 2008-03-13 2014-10-01 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
WO2010034590A1 (en) * 2008-09-29 2010-04-01 Biotest Ag Composition for treating disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN115814092A (zh) * 2022-12-20 2023-03-21 中国医学科学院医学生物学研究所 与急性t淋巴细胞白血病治疗相关的靶点cd28及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DK1451224T3 (da) * 2001-12-04 2012-11-19 Theramab Llc Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL

Also Published As

Publication number Publication date
US20070122410A1 (en) 2007-05-31
US20130078257A1 (en) 2013-03-28
US20060008457A1 (en) 2006-01-12
DE10352900A1 (de) 2005-06-16
US20160017039A1 (en) 2016-01-21
US9119840B2 (en) 2015-09-01
PT1600460E (pt) 2012-10-09
ES2391455T3 (es) 2012-11-26
EP1600460A1 (de) 2005-11-30
EP1600460B1 (de) 2012-08-15

Similar Documents

Publication Publication Date Title
DK1600460T3 (da) Anvendelse af et aktivt stof, der binder sig til CD28, til fremstilling af en farmaceutisk sammensætning til behandling af B-CLL
LTC1725537I2 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
DK1572874T3 (da) Antistoffer, der immunospecifikt binder til TRAIL receptorer
DK1830956T3 (da) Fremgangsmåde til forberedelse af katalytiske materialer
DK1755555T3 (da) Fremgangsmåde til fremstilling af tørpulversammensætninger af glycopyrrolat
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
AP2006003534A0 (en) Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
DK1816935T3 (da) System med kapsel, der har forseglingsmidler
DK1505974T3 (da) Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
IL169193A0 (en) Condensed furan compounds
HK1090308A1 (en) Directly compressible pharmaceutical composition for the oral admnistration of cci-779
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
ATE380166T1 (de) Hydraulisches bindemittel
DK1612200T3 (da) Gødningssammensætning
GEP20115239B (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
DK1957517T3 (da) Anvendelse af peptider, der binder til TPO-receptor
DK1725223T3 (da) Anvendelse af antagonister til CB1-receptoren til fremstilling af en sammensætning, der er anvendelig til behandling af leversygdomme
DK1761130T3 (da) Emballeret pulversammensætning til bageri
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
NO20041865L (no) Pressbar sprengstoffkomposisjon
HK1094575A1 (en) A process for the preparation of phenyltetrazole derivatives
DK1786913T3 (da) Fremgangsmåde til fremstilling af diarylcycloalkylderivater